BREAKING NEWS: New International Medical Advisory Board Read News
We focus on improving breast cancer survival rates by detecting cancers earlier and making treatment more effective and less intense.
FDA cleared for use on all major 2D and 3D mammography systems.
Here’s a short introduction to what we do
Trusted in more than 30 countries
FDA cleared and CE marked for 2D and 3D mammography
The most independent peer reviewed publications in breast AI
Proven multivendor compatibility
Integrated with most workstations
Experience the benefit of our continuously evolving deep learning algorithm
Accuracy.
Workload Reduction.
Results.
"Transpara has the potential to detect specific cancers earlier. I can think of 1-2 recent cases with calcifications, where Transpara detected a cancer earlier that was not easily visible on a mammogram."
"Transpara increases my confidence and efficiency going through a screening mammography session. I have more focus especially with the higher risk cases thanks to their Intuitive Triage software."
"I use Transpara all the time, and won't read another 3D mammogram without it. The product fits seamlessly into our workflow, and we have found over time it has increased our mammography workflow. Thanks to the technology's score card we are also able to focus on those high risk patients first, and get those patients the care they may need faster."
“Transpara may allow discriminating studies, which require more attention and selection of those, which may be handled with single reading for example. It may thus contribute significantly to both risk adapted screening and optimum assignment of resources."
"We are at the forefront of one of the first prospective studies with Transpara. As we will implement Transpara in a real-life screening setting in Ostergotland County, we aim to improve the quality of the breast cancer screening program while at the same time safely reduce the workload of breast radiologists."
Client undergoes mammogram
Transpara analyses mammogram scan
Radiologist reads with support from Transpara, increasing confidence in decision
Make more accurate and consistent decision
Nijmegen, The Netherlands: Date March 1, 2023: Transpara® from ScreenPoint Medical is now being used daily in more than 30
Read moreStudies Being Presented at RSNA Shows that the Use of Transpara May Safely Reduce Workload and Maintain Accurate Cancer Detection in
Read moreThe Scandinavian key leaders of AI in breast imaging presented their research at the ScreenPoint symposium at EUSOBI 2022
Read moreScreenPoint Medical, the company that developed the world leading Transpara® AI breast care system, today announced the launch of its
Read moreScandinavia is at the forefront of research and adoption of AI in breast screening. Are you attending EUSOBI 2022 in
Read moreTranspara, the world’s leading artificial intelligence (AI) breast care software, has now reached a major new milestone, helping radiologists read
Read more
